Compare SKIL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | BTAI |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | 2261 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 35.6M |
| IPO Year | N/A | 2018 |
| Metric | SKIL | BTAI |
|---|---|---|
| Price | $3.62 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.25 |
| AVG Volume (30 Days) | 123.9K | ★ 1.2M |
| Earning Date | 04-13-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $1.17 |
| 52 Week High | $23.00 | $8.08 |
| Indicator | SKIL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.00 | 43.74 |
| Support Level | N/A | $1.44 |
| Resistance Level | $4.84 | $2.22 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 14.89 | 13.16 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.